AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10488988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 0.12 mg
Number of subjects: 24
Study 10488988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 0.24 mg
Number of subjects: 24
Study 10488988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10488988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (both dosages)
Number of subjects: 24
Study 10488988 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigeminal stimuli
Number of subjects: 24
Study 8945044 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1400T lead (impregnated with steroid)
Number of subjects: 54
Study 8945044 — intervention group
Group type: COMPARATOR
Intervention: Model 1401T lead (not impregnated with steroid)
Number of subjects: 54
Study 8945044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacesetter Microny SR + 2425T VVIR pacemaker
Number of subjects: 54
Study 1365502 — intervention group
Group type: EXPERIMENTAL
Intervention: roentgenovascular dilatation of one or two coronary arteries
Number of subjects: 40
Study 1365502 — intervention group
Group type: EXPERIMENTAL
Intervention: noninvasive tests
Number of subjects: 40
Study 1365502 — intervention group
Group type: COMPARATOR
Intervention: Control coronarography
Number of subjects: 40
Study 6358146 — intervention group
Group type: EXPERIMENTAL
Intervention: Starchex
Number of subjects: 5
Study 6358146 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorex
Number of subjects: 5
Study 6358146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31627736 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level WASH intervention
Number of subjects: 0
Study 31627736 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular deworming with albendazole
Number of subjects: 0
Study 31627736 — intervention group
Group type: COMPARATOR
Intervention: Household characteristics
Number of subjects: 0
Study 31627736 — intervention group
Group type: COMPARATOR
Intervention: Infection with hookworm (Necator americanus)
Number of subjects: 0
Study 30048306 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (nutritional counseling and exercise)
Number of subjects: 118
Study 30048306 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 118
Study 30048306 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 118
Study 27384580 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplement (SUPP)
Number of subjects: 10
Study 27384580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 24782447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular suppressant (dimenhydrinate 50 mg per day)
Number of subjects: 150
Study 24782447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 24782447 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 150
Study 22048284 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA with remifentanil-propofol (group R)
Number of subjects: 40
Study 22048284 — intervention group
Group type: COMPARATOR
Intervention: TIVA with fentanyl-propofol (group F)
Number of subjects: 40
Study 19114222 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (n=18)
Number of subjects: 98
Study 19114222 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (control, n=20)
Number of subjects: 98
Study 17172316 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity combined endurance and resistance exercise training program (16 weeks, 3 endurance sessions and 2 resistance sessions per week)
Number of subjects: 9
Study 14668570 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing with cilnidipine
Number of subjects: 13
Study 14668570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime dosing with cilnidipine
Number of subjects: 13
Study 12482110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed estrogen therapy (Aerodiol®)
Number of subjects: 659
Study 9797183 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 14
Study 7639204 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Diagnostic Interview Schedule (C-DIS)
Number of subjects: 173
Study 7639204 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Clinical Interview for DSM-III-R (SCID)
Number of subjects: 173
Study 7639204 — intervention group
Group type: COMPARATOR
Intervention: C-DIS
Number of subjects: 173
Study 7639204 — intervention group
Group type: COMPARATOR
Intervention: SCID
Number of subjects: 173
Study 2577283 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 19
Study 2577283 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 19
Study 2577283 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin and Xamoterol
Number of subjects: 19
Study 2577283 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin or Xamoterol
Number of subjects: 19
Study 339940 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy plus immunotherapy with BCG and irradiated allogeneic blast cells
Number of subjects: 71
Study 339940 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone
Number of subjects: 71
Study 339940 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with BCG and irradiated allogeneic blast cells
Number of subjects: 71
Study 31735108 — intervention group
Group type: EXPERIMENTAL
Intervention: Venography plus angioplasty (n=86)
Number of subjects: 130
Study 31735108 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable venograms (n=38)
Number of subjects: 130
Study 31735108 — intervention group
Group type: COMPARATOR
Intervention: Venography (sham; n=44)
Number of subjects: 130
Study 31534559 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorization Program (CP) training for 10-12 weeks targeting concept formation, object categorization, and decision-making abilities.
Number of subjects: 58
Study 31534559 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorization Program (CP) training for older adults (experimental group).
Number of subjects: 58
Study 31534559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CP training).
Number of subjects: 58
Study 27467517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (NHE)
Number of subjects: 47
Study 27467517 — intervention group
Group type: EXPERIMENTAL
Intervention: Russian belt (RB)
Number of subjects: 47
Study 27467517 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 47
Study 26537599 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Therapy (FT)
Number of subjects: 0
Study 26537599 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 23386704 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (4000 IU/day)
Number of subjects: 116
Study 23386704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 23386704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (High-dose vitamin D and Placebo)
Number of subjects: 116
Study 21499826 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood SES (socio-economic status)
Number of subjects: 15889
Study 21499826 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood walkability
Number of subjects: 15889
Study 21499826 — intervention group
Group type: COMPARATOR
Intervention: Neighborhood SES (highest decile)
Number of subjects: 15889
Study 19802686 — intervention group
Group type: EXPERIMENTAL
Intervention: One-leg standing (OLS) test
Number of subjects: 0
Study 19802686 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to improve OLS time
Number of subjects: 0
Study 17618934 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (n=33)
Number of subjects: 51
Study 17618934 — intervention group
Group type: COMPARATOR
Intervention: Early loading (n=21)
Number of subjects: 51
Study 15172090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg per day)
Number of subjects: 30
Study 15172090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11676155 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TMLR)
Number of subjects: 0
Study 11676155 — intervention group
Group type: COMPARATOR
Intervention: Conservative medical treatment
Number of subjects: 0
Study 9578967 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevating peak inspiratory pressure (PIP) in Group 1
Number of subjects: 22
Study 9578967 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonging inspiratory time (T1) in Group 1
Number of subjects: 22
Study 9578967 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising positive end expiratory pressure (PEEP) in Group 2
Number of subjects: 22
Study 8066558 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (3 mg orally twice a day)
Number of subjects: 19
Study 8066558 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 19
Study 3378222 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cis-diamminedichloroplatinum(II) at 30 mg/m2/day for 5 days
Number of subjects: 11
Study 3378222 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus of cis-diamminedichloroplatinum(II) at 30 mg/m2/day for 5 days
Number of subjects: 11
Study 3378222 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cis-diamminedichloroplatinum(II)
Number of subjects: 11
Study 3378222 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus of cis-diamminedichloroplatinum(II)
Number of subjects: 11
Study 28951057 — intervention group
Group type: EXPERIMENTAL
Intervention: Grab-and-go style breakfast carts and policies
Number of subjects: 364
Study 27824882 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) group; participants received two oral-fluid-based HIV test kits and were encouraged to distribute one to their male partner or use both for testing as a couple.
Number of subjects: 600
Study 27824882 — intervention group
Group type: COMPARATOR
Intervention: Comparison group; participants received an invitation card for clinic-based HIV testing and were encouraged to distribute the card to their male partner.
Number of subjects: 600
Study 27824882 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) group; participants received two oral-fluid-based HIV test kits.
Number of subjects: 600
Study 27824882 — intervention group
Group type: COMPARATOR
Intervention: Comparison group; participants received an invitation card for clinic-based HIV testing.
Number of subjects: 600
Study 24731493 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 12
Study 24731493 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (Control)
Number of subjects: 12
Study 23853004 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet
Number of subjects: 183
Study 23853004 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup
Number of subjects: 183
Study 23853004 — intervention group
Group type: COMPARATOR
Intervention: Suspension
Number of subjects: 183
Study 23853004 — intervention group
Group type: COMPARATOR
Intervention: Powder
Number of subjects: 183
Study 23853004 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall formulations
Number of subjects: 183
Study 20220530 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource facilitation (RF)
Number of subjects: 22
Study 20220530 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 22
Study 18801398 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg H5 HA with AlPO4 adjuvant
Number of subjects: 150
Study 18801398 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 microg H5 HA with AlPO4 adjuvant
Number of subjects: 150
Study 16529658 — intervention group
Group type: EXPERIMENTAL
Intervention: All-arthroscopic repair
Number of subjects: 250
Study 16529658 — intervention group
Group type: COMPARATOR
Intervention: Mini-open repair
Number of subjects: 250
Study 12810608 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes
Number of subjects: 21
Study 12810608 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 21
Study 11732148 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate (4 mg/kg on day 0 and 2 mg/kg on days 1‐4)
Number of subjects: 62
Study 11732148 — intervention group
Group type: COMPARATOR
Intervention: mefloquine (10 mg/kg followed by 5 mg/kg at 6 h)
Number of subjects: 62
Study 11732148 — intervention group
Group type: COMPARATOR
Intervention: mefloquine
Number of subjects: 62
Study 11732148 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate
Number of subjects: 62
Study 11732148 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate plus mefloquine
Number of subjects: 62
Study 9203892 — intervention group
Group type: EXPERIMENTAL
Intervention: Glossopharyngeal nerve block with bupivacaine 0.5% and adrenaline 1:200,000
Number of subjects: 108
Study 9203892 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone (no glossopharyngeal nerve block)
Number of subjects: 108
Study 7963156 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (single oral dose)
Number of subjects: 0
Study 7963156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2824031 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-interferon
Number of subjects: 18
Study 2824031 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 29879948 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐STAND intervention (12-week program with 6 health coaching contacts, a study workbook, a Jawbone UP band, and feedback from an activPAL device)
Number of subjects: 22
Study 28095077 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (S)
Number of subjects: 16
Study 28095077 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 16
Study 26575060 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (12 mg/kg/d for 5 days)
Number of subjects: 607
Study 26575060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study 23237386 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Tomato intervention
Number of subjects: 658
Study 23237386 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 658
Study 21146469 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 139
Study 21146469 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 139
Study 21146469 — intervention group
Group type: EXPERIMENTAL
Intervention: Both opioids
Number of subjects: 139
Study 21146469 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 139
Study 18344552 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.175% with 0.5 mg kg(‐1) S(+)‐ketamine (Group 2)
Number of subjects: 164
Study 18344552 — intervention group
Group type: COMPARATOR
Intervention: levobupivacaine 0.15% with 0.5 mg kg(‐1) S(+)‐ketamine (Group 1)
Number of subjects: 164
Study 18344552 — intervention group
Group type: COMPARATOR
Intervention: levobupivacaine 0.2% (Group 3)
Number of subjects: 164
Study 17152422 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing
Number of subjects: 160
Study 17152422 — intervention group
Group type: EXPERIMENTAL
Intervention: Steristrips
Number of subjects: 160
Study 17152422 — intervention group
Group type: COMPARATOR
Intervention: Simple dressing
Number of subjects: 160
Study 14769156 — intervention group
Group type: EXPERIMENTAL
Intervention: Game (Jugando en salud: dengue) practiced three times a week for 60 days with theoretical materials about dengue
Number of subjects: 621
Study 14769156 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical materials only (group no. 2)
Number of subjects: 621
Study 14769156 — intervention group
Group type: COMPARATOR
Intervention: Regular learning program (control group)
Number of subjects: 621
Study 11144866 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate feedback
Number of subjects: 40
Study 11144866 — intervention group
Group type: EXPERIMENTAL
Intervention: High performance
Number of subjects: 40
Study 11144866 — intervention group
Group type: EXPERIMENTAL
Intervention: Low performance
Number of subjects: 40
Study 11144866 — intervention group
Group type: COMPARATOR
Intervention: No exercise control
Number of subjects: 40
Study 9126664 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 0
Study 9126664 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 20 mg daily
Number of subjects: 0
Study 9126664 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg and 20 mg
Number of subjects: 0
Study 9126664 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 20 mg and 40 mg
Number of subjects: 0
Study 31623184 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS)
Number of subjects: 18
Study 31623184 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Starch with high fiber (RSF)
Number of subjects: 18
Study 31623184 — intervention group
Group type: COMPARATOR
Intervention: Digestible Starch (DS)
Number of subjects: 18
Study 30261980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictogram medals attached to inhalers in the intervention group
Number of subjects: 219
Study 30261980 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pictogram medals)
Number of subjects: 219
Study 27142768 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure-of-eight bandage
Number of subjects: 110
Study 27142768 — intervention group
Group type: COMPARATOR
Intervention: Arm sling
Number of subjects: 110
Study 24045343 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham-treated study eyes
Number of subjects: 214
Study 24045343 — intervention group
Group type: COMPARATOR
Intervention: Untreated fellow eyes with dry AMD
Number of subjects: 214
Study 22578664 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor therapy with professional performers (ElderClowns) and trained facility staff (LaughterBosses) for a minimum of nine two-hour sessions over 12 weeks.
Number of subjects: 398
Study 22578664 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) with no formal humor therapy.
Number of subjects: 398
Study 19082329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioplegia with procaine (Group B)
Number of subjects: 18
Study 19082329 — intervention group
Group type: COMPARATOR
Intervention: Cardioplegia without procaine (Group A)
Number of subjects: 18
Study 16525815 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg potassium bromide daily for 20 weeks
Number of subjects: 24
Study 16525815 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg potassium bromide daily for 20 weeks
Number of subjects: 24
Study 16525815 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg potassium bromide daily for 20 weeks
Number of subjects: 24
Study 12720588 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g ALNA/d
Number of subjects: 40
Study 12720588 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.44 g EPA+DHA/d
Number of subjects: 40
Study 12720588 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.94 g EPA+DHA/d
Number of subjects: 40
Study 12720588 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.9 g EPA+DHA/d
Number of subjects: 40
Study 12720588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11256241 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg orally every 12 hours for 7 days
Number of subjects: 142
Study 11256241 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir 200 mg orally every 5 hours for 7 days
Number of subjects: 142
Study 9403919 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (6 sessions of progressive muscle relaxation and imagery)
Number of subjects: 22
Study 9403919 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (routine medical care)
Number of subjects: 22
Study 8513908 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal sufentanil (IS), 150 micrograms
Number of subjects: 36
Study 8513908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (IM), 50 micrograms kg‐1
Number of subjects: 36
Study 2450187 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg orally) during a 6‐h infusion of aprotinin (2 x 10(6) KIU)
Number of subjects: 25
Study 2450187 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingually)
Number of subjects: 25
Study 2450187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31869478 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Life preparation (minimum 15 minutes)
Number of subjects: 59
Study 31869478 — intervention group
Group type: COMPARATOR
Intervention: Standard practice without Child Life preparation (control)
Number of subjects: 59
Study 29352306 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus GEMOX (P-GEMOX)
Number of subjects: 57
Study 29352306 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR amplification
Number of subjects: 57
Study 29352306 — intervention group
Group type: COMPARATOR
Intervention: EGFR mutations (ECD and TKD)
Number of subjects: 57
Study 26660279 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi DBS
Number of subjects: 128
Study 26660279 — intervention group
Group type: EXPERIMENTAL
Intervention: STN DBS
Number of subjects: 128
Study 25572038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-rich dietary supplement from egg protein hydrolysate (0.5 g twice per day for 19 days)
Number of subjects: 59
Study 25572038 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 g twice per day for 19 days)
Number of subjects: 59
Study 24325057 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminoplasty combined Modified Buyang Huanwu Decoction (MBHD)
Number of subjects: 32
Study 24325057 — intervention group
Group type: COMPARATOR
Intervention: Laminoplasty
Number of subjects: 32
Study 20600734 — intervention group
Group type: EXPERIMENTAL
Intervention: CM‐β‐CyD (carboxymethyl‐β‐cyclodextrin)
Number of subjects: 0
Study 20600734 — intervention group
Group type: COMPARATOR
Intervention: SBE‐β‐CyD (sulfobutyl‐ether‐β‐cyclodextrin)
Number of subjects: 0
Study 20600734 — intervention group
Group type: COMPARATOR
Intervention: Plain drug tablets (FMT)
Number of subjects: 0